Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
4 hedge funds and large institutions have $173K invested in Bellicum Pharmaceuticals, Inc. in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 23 closing their positions.
63% less capital invested
Capital invested by funds: $470K → $173K (-$297K)
84% less funds holding
Funds holding: 25 → 4 (-21)
91% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$243K |
| 2 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$6.16K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$148K |
| 2 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
-$108K |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$82.2K |
| 4 |
BlackRock
New York
|
-$25K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$24K |
BLCM Hedge Fund Activity: Q2 2023 in Review
4 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q2 2023, worth a combined $173K — down 63% from $470K a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of BLCM and 2 opened new positions — a net loss of 21 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was Boxer Capital, opening a new position worth an estimated $243K. The largest seller was Ikarian Capital, exiting entirely with an estimated $148K sold.
- 4 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q2 2023, down from 25 in Q1 2023.
- Funds reported $173K of Bellicum Pharmaceuticals, Inc. stock for Q2 2023, down 63% quarter-over-quarter.
- 2 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q2 2023 and 23 closed out, a net change of -21 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q2 2023 was Boxer Capital, an estimated $243K added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q2 2023 was Ikarian Capital, an estimated $148K sold.
Based on aggregated 13F filings for Q2 2023.